{"id":60060,"date":"2024-09-24T01:04:25","date_gmt":"2024-09-23T23:04:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/"},"modified":"2024-09-24T01:04:25","modified_gmt":"2024-09-23T23:04:25","slug":"neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/","title":{"rendered":"NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation"},"content":{"rendered":"
\n

\nCompany will host business update call on Sept. 24, 2024, at 8:30 a.m. ET\n<\/p>\n

FT. MYERS, Fla.–(BUSINESS WIRE)–NeoGenomics, Inc. (NASDAQ: NEO), <\/b>a leading oncology testing services company, today issued the following statement in response to inquiries:\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nNeoGenomics has cleared the feasibility stage with a new version of its RaDaR\u00ae<\/sup> technology and has resolved litigation with Natera regarding RaDaR 1.0. The Company will host a business update conference call and webcast on Tuesday, Sept. 24, 2024, beginning at 8:30 a.m. Eastern Time.\n<\/p>\n

\nThe accelerated progress of the new RaDaR technology provided the Company the opportunity to negotiate a resolution with Natera as to RaDaR 1.0. The settlement, while confidential, is not material to the Company\u2019s bottom line and does not impact its adjusted EBITDA guidance range or liquidity expectations.\n<\/p>\n

\nThe live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com<\/a>. The webcast will be archived and available for replay shortly after the conclusion of the call.\n<\/p>\n

\nTo access the live call via telephone, dial (877) 545-0523 (domestic) or (973) 528-0016 (international) at least five minutes prior to the call. The participant access code is 196876.\n<\/p>\n

\nAbout NeoGenomics, Inc.<\/b>\n<\/p>\n

\nNeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.\n<\/p>\n

\nHeadquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact<\/b>
Kendra Sweeney
\n
kendra.sweeney@neogenomics.com<\/a>\n<\/p>\n

\nMedia Contact<\/b>
Andrea Sampson
\n
asampson@sampsonprgroup.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Company will host business update call on Sept. 24, 2024, at 8:30 a.m. ET FT. MYERS, Fla.–(BUSINESS WIRE)–NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today issued the following statement in response to inquiries: NeoGenomics has cleared the feasibility stage with a new version of its RaDaR\u00ae technology and has resolved litigation with … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60060","6":"format-standard","7":"category-industry"},"yoast_head":"\nNeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Company will host business update call on Sept. 24, 2024, at 8:30 a.m. ET FT. MYERS, Fla.–(BUSINESS WIRE)–NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today issued the following statement in response to inquiries: NeoGenomics has cleared the feasibility stage with a new version of its RaDaR\u00ae technology and has resolved litigation with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-23T23:04:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240923921828\/en\/2251640\/22\/NeoGenomics.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation\",\"datePublished\":\"2024-09-23T23:04:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\\\/\"},\"wordCount\":356,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240923921828\\\/en\\\/2251640\\\/22\\\/NeoGenomics.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\\\/\",\"name\":\"NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240923921828\\\/en\\\/2251640\\\/22\\\/NeoGenomics.jpg\",\"datePublished\":\"2024-09-23T23:04:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240923921828\\\/en\\\/2251640\\\/22\\\/NeoGenomics.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240923921828\\\/en\\\/2251640\\\/22\\\/NeoGenomics.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/","og_locale":"en_US","og_type":"article","og_title":"NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation - Pharma Trend","og_description":"Company will host business update call on Sept. 24, 2024, at 8:30 a.m. ET FT. MYERS, Fla.–(BUSINESS WIRE)–NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today issued the following statement in response to inquiries: NeoGenomics has cleared the feasibility stage with a new version of its RaDaR\u00ae technology and has resolved litigation with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/","og_site_name":"Pharma Trend","article_published_time":"2024-09-23T23:04:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240923921828\/en\/2251640\/22\/NeoGenomics.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation","datePublished":"2024-09-23T23:04:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/"},"wordCount":356,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240923921828\/en\/2251640\/22\/NeoGenomics.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/","url":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/","name":"NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240923921828\/en\/2251640\/22\/NeoGenomics.jpg","datePublished":"2024-09-23T23:04:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240923921828\/en\/2251640\/22\/NeoGenomics.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240923921828\/en\/2251640\/22\/NeoGenomics.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/neogenomics-announces-new-radar-technology-and-resolution-of-radar-1-0-litigation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60060"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60060\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}